Ruxolitinib Cream in the Treatment of Cutaneous Lichen Planus: A Prospective, Open-Label Study

Brumfiel, Caitlin M.; Patel, Meera H.; Severson, Kevin J.; Zhang, Nan; Li, Xing; Quillen, Jaxon; Zunich, Samantha M.; Branch, Emily L.; Nelson, Sara; Pittelkow, Mark R.; Mangold, Aaron R.

doi:10.1016/j.jid.2022.01.015

Cited by 24 publications

(18 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LP is also an Th1, interferon gamma–driven process that resolves with selective targeting of interferon gamma–associated genes. 10 In our case, the response to intralesional triamcinolone possibly correlates with diminution of the Th1 response and, therefore, the antitumoral response, which may have led to unmasking of a BCC.…”

Section: Discussionmentioning

confidence: 54%

Basal cell carcinoma arising within an alopecic patch of lichen planopilaris

Boudreaux¹,

Mangold²,

Nelson³

et al. 2022

JAAD Case Reports

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 54%

Basal cell carcinoma arising within an alopecic patch of lichen planopilaris

Boudreaux¹,

Mangold²,

Nelson³

et al. 2022

JAAD Case Reports

Self Cite

View full text Add to dashboard Cite

“…Topical ruxolitinib has also been reported as an effective new therapy for vitiligo and lichen planus—diseases driven by elevated levels of interferon gamma, an upstream effector of JAKs. 8 , 9 In these reports, ruxolitinib 1.5% cream provided significant repigmentation 8 and rapid improvement 9 of facial vitiligo and cutaneous lichen planus, respectively. To our knowledge, this is the first report describing the excellent efficacy of ruxolitinib in a patient with significant SD and concomitant rosacea.…”

Section: Discussionmentioning

confidence: 94%

Topical ruxolitinib in the treatment of refractory facial seborrheic dermatitis

2022

View full text Add to dashboard Cite

“…The pathogenesis is not completely known; however, the upregulation of JAK2/STAT1 in keratinocytes and dependent cytokines, such as IFN-γ, seem to play a role ( 37 ). The use of topical ruxolitinib for lichen planus was tested in a phase II trial ( 38 ), and 1 case report demonstrated that oral tofacitinib dramatically improved pruritus in patients with the disease ( 39 ).…”

Section: Resultsmentioning

confidence: 99%

Itch and Janus Kinase Inhibitors

et al. 2023

View full text Add to dashboard Cite

Itch is a common skin symptom, with complex aetiology and pathogenesis. It is mediated by 2 pathways, the histaminergic and non-histaminergic pathways. Chronic itch is understood to be processed by the latter and is difficult to treat with traditional pruritus therapies. The Janus kinase and signal transducer and activator of transcription pathway is a signalling mechanism that regulates gene expression through various cytokines. Janus kinase inhibitors, which have been tested and used for several autoimmune diseases, have also been shown to be effective for itch through clinical trials and case reports. Janus kinase inhibitors could be a good choice for pruritus in atopic dermatitis, psoriasis, and other diseases, such as prurigo nodularis and lichen planus, with rapid itch relief compared with conventional treatments. The most common adverse effects reported include nasopharyngitis, acne, and elevated blood creatine phosphokinase levels. Janus kinase inhibitors are currently prescribed with warnings about a potential increase in malignancies and cardiovascular diseases and usage in people of older ages. This review aims to provide knowledge about itch and the Janus kinase and signal transducer and activator of transcription pathway and to analyse the current evidence for itch relief by Janus kinase inhibitors.

show abstract

Ruxolitinib Cream in the Treatment of Cutaneous Lichen Planus: A Prospective, Open-Label Study

Cited by 24 publications

References 13 publications

Basal cell carcinoma arising within an alopecic patch of lichen planopilaris

Basal cell carcinoma arising within an alopecic patch of lichen planopilaris

Topical ruxolitinib in the treatment of refractory facial seborrheic dermatitis

Itch and Janus Kinase Inhibitors

Contact Info

Product

Resources

About